Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $116 million, down from $136.8 million in Q4 2024, primarily due to new state regulations and compliance standards [9][10] - Full year revenue increased by 7% to $615 million, driven by kiosk expansion and growth in median transaction size [10] - Gross profit for Q4 2025 was $15.3 million, compared to $23.5 million in Q4 2024, with a gross margin of 13.2% [10][11] - GAAP net loss for Q4 2025 was $24.9 million, compared to a net income of $5.4 million in Q4 2024 [11] - Adjusted EBITDA for Q4 was $1.6 million, down from $13 million in the prior year, while full year adjusted EBITDA increased by 42% to $56.4 million [12] Business Line Data and Key Metrics Changes - The number of installed kiosks at the end of 2025 was 9,721, up 15% from the end of 2024 [10] - Median transaction size grew to $400, an increase of 43% from the end of 2024 [10] - The company completed the transition of assets from National Bitcoin ATM, adding over 500 kiosks to its network [5] Market Data and Key Metrics Changes - The company ended Q4 with approximately 9,700 active machines, reflecting both organic growth and targeted acquisitions [4] - The company expects continued regulatory activity at the state level in 2026, which may introduce additional transaction limits [7] Company Strategy and Development Direction - The company is diversifying beyond Bitcoin ATMs by leveraging its payment infrastructure and compliance capabilities, with recent acquisitions including a peer-to-peer social betting platform and a business advance platform [8] - The company aims to adapt to regulatory changes while focusing on cost containment and fleet optimization [15] Management's Comments on Operating Environment and Future Outlook - Management anticipates a challenging year in 2026 for the core Bitcoin ATM business, expecting revenue to decline by 30%-40% year-over-year due to regulatory changes [15] - By the end of 2026, management expects 80%-90% of states to have established their regulatory stance [25] Other Important Information - Cash and cash equivalents increased to $76.6 million as of December 31, 2025, compared to $31.0 million at the end of 2024 [13] - The company completed a $15 million registered direct offering of its Class A common stock during Q4 [13] Q&A Session Summary Question: Can you unpack the 2026 revenue guidance and underlying kiosk growth assumptions? - Management indicated that revenue decline is uncertain due to potential regulatory changes, with kiosk numbers likely remaining flat or slightly down [18] Question: How will new Bitcoin ATM regulations affect the M&A landscape? - Management stated that they may be opportunistic in M&A depending on how competitors react to regulatory changes, but they are not actively seeking acquisitions [21] Question: What is the regulatory landscape expected to look like by the end of 2026? - Management believes that by the end of 2026, 80%-90% of states will have made initial regulatory decisions [25] Question: How do current regulations affect international market ambitions? - Management confirmed ongoing efforts in international expansion, with hopes for successful launches in new countries despite varying regulatory environments [26]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $116 million, down from $136.8 million in Q4 2024, primarily due to new state regulations and compliance standards [9][10] - Full year revenue increased by 7% to $615 million, driven by kiosk expansion and growth in median transaction size [10] - Gross profit for Q4 2025 was $15.3 million, compared to $23.5 million in Q4 2024, with a gross margin of 13.2% [10][11] - GAAP net loss for Q4 2025 was $24.9 million, compared to a net income of $5.4 million in Q4 2024 [11] - Adjusted EBITDA for Q4 was $1.6 million, down from $13 million in the prior year, while full year adjusted EBITDA increased by 42% to $56.4 million [12] Business Line Data and Key Metrics Changes - The number of installed kiosks at the end of 2025 was 9,721, up 15% from the end of 2024 [10] - Median transaction size grew to $400, up 43% from the end of 2024 [10] - The company completed the transition of assets from National Bitcoin ATM, adding over 500 kiosks to its network [5] Market Data and Key Metrics Changes - The company ended Q4 with approximately 9,700 active machines, reflecting both organic growth and targeted acquisitions [4] - The company expects continued regulatory activity at the state level in 2026, which may introduce additional transaction limits [7] Company Strategy and Development Direction - The company is diversifying beyond Bitcoin ATMs by leveraging its payment infrastructure and compliance capabilities, with recent acquisitions including a peer-to-peer social betting platform and a business advance platform [8] - The company aims to adapt to regulatory changes while focusing on cost containment and fleet optimization [15] Management's Comments on Operating Environment and Future Outlook - Management anticipates a challenging year in 2026 for the core Bitcoin ATM business, expecting revenue to decline between 30%-40% year-over-year due to regulatory changes [15] - The company believes that the regulatory measures will ultimately raise industry standards and reinforce its advantages in compliance and scale [7] Other Important Information - Cash and cash equivalents increased to $76.6 million as of December 31, 2025, compared to $31.0 million at the end of 2024 [13] - The company completed a $15 million registered direct offering of its Class A common stock during Q4 [13] Q&A Session Summary Question: Can you unpack the 2026 revenue guidance and underlying kiosk growth assumptions? - Management indicated that the revenue decline is uncertain due to potential regulatory changes, with kiosk numbers likely remaining flat or slightly down [18] Question: How do you envision new Bitcoin ATM regulations changing the M&A landscape? - Management stated that they may be opportunistic in M&A depending on how competitors react to regulatory changes, but they are not actively seeking acquisitions [21] Question: What is the regulatory landscape expected to look like by the end of 2026? - Management believes that 80%-90% of states will have decided on their regulatory stance by the end of 2026, with less activity expected in 2027 [25] Question: How do regulatory actions affect views on international markets? - Management noted that international markets do not currently show similar regulatory issues as the U.S. and they are actively working on expansion in two more countries [26]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $116 million, down from $136.8 million in Q4 2024, primarily due to new state regulations and enhanced compliance standards [9] - Full year revenue increased by 7% to $615 million, driven by kiosk expansion and growth in median transaction size [9] - Gross profit for Q4 2025 was $15.3 million, compared to $23.5 million in Q4 2024, with a gross margin of 13.2% [10] - GAAP net loss for Q4 2025 was $24.9 million, compared to a net income of $5.4 million in Q4 2024 [11] - Adjusted EBITDA for Q4 was $1.6 million, down from $13 million in the prior year, while full year adjusted EBITDA increased by 42% to $56.4 million [12] Business Line Data and Key Metrics Changes - The number of installed kiosks at the end of 2025 was 9,721, up 15% from the end of 2024 [10] - Median transaction size grew to $400, up 43% from the end of 2024 [10] - The company completed the transition of assets from National Bitcoin ATM, adding over 500 kiosks to its network [5] Market Data and Key Metrics Changes - The company ended Q4 with approximately 9,700 active machines, reflecting both organic growth and targeted acquisitions [4] - The company expects continued regulatory activity at the state level in 2026, which may introduce additional transaction limits [6] Company Strategy and Development Direction - The company is diversifying beyond Bitcoin ATMs by leveraging existing payment infrastructure and compliance capabilities [8] - Recent acquisitions include Kutt, a peer-to-peer social betting platform, and the launch of ReadyBucks, a standalone business advance platform [8] - The company aims to adapt to regulatory changes while focusing on cost containment and fleet optimization [15] Management's Comments on Operating Environment and Future Outlook - Management anticipates a challenging year in 2026 for the core Bitcoin ATM business, expecting revenue to decline by 30%-40% year-over-year [15] - The company believes that regulatory measures will ultimately raise industry standards and reinforce compliance advantages [6] Other Important Information - Cash, cash equivalents, and cryptocurrencies increased to $76.6 million as of December 31, 2025, compared to $31.0 million at the end of 2024 [12] - Debt at the end of Q4 2025 was $62.5 million, up from $60.9 million at the end of 2024 [13] Q&A Session Summary Question: Can you unpack the 2026 revenue guidance and underlying kiosk growth assumptions? - Management indicated that the revenue decline is uncertain due to potential regulatory changes, with kiosk numbers likely remaining flat or slightly down [18] Question: How will new Bitcoin ATM regulations affect the M&A landscape? - Management stated that they may be opportunistic in M&A depending on how competitors react to regulatory changes, but are not actively seeking acquisitions [20] Question: What is the expected regulatory landscape by the end of 2026? - Management believes that 80%-90% of states will have established their regulatory stance by the end of 2026, with less activity expected in 2027 [25] Question: How do regulatory actions in the U.S. affect international market ambitions? - Management noted that international markets do not currently exhibit the same regulatory issues as the U.S. and they are still pursuing expansion in two additional countries [26]

Financial Data and Key Metrics Changes - Fourth quarter revenue was $1.75 billion, representing an organic contraction of approximately 6% due to a $60 million reduction from the low-margin Cloud One program and a $45 million headwind from a non-recurring software license sale in the prior year [17] - Full year revenue was $7.26 billion, declining approximately 3% organically, primarily due to the decision to no-bid low-margin Cloud One revenue, which was a $200 million headwind for the year [17] - Adjusted EBITDA for the fourth quarter was $181 million, resulting in a margin of 10.3%, contributing to a full year margin of 9.7%, which is roughly 20 basis points ahead of guidance [18] - Free cash flow was $336 million in the quarter and $577 million for the full year, demonstrating strong cash conversion [18] Business Line Data and Key Metrics Changes - The company is focusing on higher-margin programs and has seen improved performance in its civilian enterprise IT portfolio, which has driven stronger win rates [11] - The large enterprise IT market is expected to shrink from 17% of company revenues in FY 2025 to an anticipated 10% in FY 2027, indicating a strategic shift away from low-margin work [11] Market Data and Key Metrics Changes - The company expects total revenue in FY 2027 to be in the range of $7 billion to $7.2 billion, representing an organic contraction of 2%-4% primarily due to recompete losses [20] - The guidance for adjusted EBITDA in FY 2027 is projected to be between $705 million and $715 million, reflecting margins between 9.9%-10.1% [20] Company Strategy and Development Direction - The company is committed to aligning and focusing its portfolio, improving internal processes, and enhancing external results, with a focus on mission expertise and customer intimacy [5][6] - A new chief growth officer has been hired to prioritize business development and drive higher win rates for recompetes and new business [6] - The company aims for $25 billion-$28 billion in submissions for FY 2027, focusing on opportunities with a greater right to win and higher customer retention [8] Management's Comments on Operating Environment and Future Outlook - Management acknowledged that the operating environment remains uneven, with procurement delays and customer disruptions impacting revenue [9] - The company is optimistic about achieving a 10% adjusted EBITDA margin for FY 2027, marking the first time it has guided to a double-digit margin on a full-year basis [9] - Management emphasized the importance of innovation and investment in capabilities to meet evolving customer needs and address the threat landscape [12] Other Important Information - The company is undergoing a multi-year enterprise transformation initiative aimed at unlocking significant value and eliminating outdated business processes [21] - The leadership team is focused on executing against a $100 million cost reduction target to provide operational and financial flexibility [13] Q&A Session Summary Question: What is the most significant portfolio pivot required to align with government budget priorities? - Management indicated a need to focus on areas where the company has a right to win and where customer retention rewards innovation and strong performance [30] Question: Thoughts on FY 2027 guidance and CapEx? - Management stated that the current CapEx is adequate to meet demand signals and that they are prepared to increase capacity if customer demand arises [39][40] Question: How long will it take to build momentum in the business development process? - Management noted that while the sales cycle can be lengthy, improvements in win rates could be seen within six months [48] Question: What is the status of recompetes and their impact on revenue? - The largest recompete is the Department of State Vanguard program, with management feeling confident about retaining most of the work [97][99]

Financial Data and Key Metrics Changes - Revenue increased 77% year-over-year to $46.8 million, exceeding guidance of $44 million-$46.3 million [7] - Adjusted EBITDA was $7.3 million, surpassing guidance of $4-$5.7 million, with an Adjusted EBITDA margin of 15.6% [10] - Full year 2025 revenue increased 52% to $164.8 million, with Adjusted EBITDA of $18.1 million, representing a $27.8 million improvement year-over-year [11] - Free cash flow was $21.3 million, a $61 million improvement year-over-year, with a free cash flow margin of 12.9% [12] Business Line Data and Key Metrics Changes - The Telos ID business drove significant revenue growth, particularly from the TSA PreCheck program [17] - Secure Networks segment experienced a $14.9 million non-cash goodwill impairment due to a decline in contract backlog [8] - Cash gross margin for the quarter was 35%, improving to 36% when excluding certain charges, while cash gross margin was 41.9% [9] Market Data and Key Metrics Changes - Over 90% of revenue comes from government contracts, including the Department of Defense and other federal agencies [18] - The company’s pipeline remains strong at over $4.2 billion, with 20% of that value expected to be awarded in the first half of 2026 [20] Company Strategy and Development Direction - The company plans to continue focusing on disciplined program execution and operating expense management to drive growth and margin expansion [6] - A company-wide restructuring plan was approved to streamline operations and position for growth in 2026 [8] - The board increased share repurchase authorization from $50 million to $75 million to support capital deployment [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the durability of revenue due to well-funded government programs tied to national security and compliance [19] - The company expects another year of double-digit revenue growth in 2026, forecasting revenue growth of 14%-21% year-over-year [13] - Management acknowledged heightened scrutiny in federal spending but noted that the programs supported remain operationally essential [19] Other Important Information - The company returned $13.6 million to shareholders through share repurchases in 2025 [12] - Adjusted operating expenses are expected to decline in 2026, even as revenue continues to grow [8] Q&A Session Summary Question: Initial guidance for the year and pipeline opportunities - Management noted that existing programs are driving growth, with the confidential IT security work expanding and the IT GEMS program ramping up [26][27] Question: Gross margin assumptions for the year - Management explained that gross margin compression is due to the growth of lower-margin revenue streams and the recognition of prepaid expenses [31][33] Question: Contribution of Xacta to revenue and renewal rates - Renewal rates for Xacta are excellent, with minimal revenue loss typically experienced [39] Question: Pipeline and large contract contributions - A significant portion of the revenue growth is tied to a large DMDC contract, contributing roughly a third of the improvement from previous outlooks [45] Question: Strategies to maintain cash gross margin - Management indicated that gross margins will fluctuate based on revenue mix, but they expect to maintain a solid cash gross margin profile [50][51]

Financial Data and Key Metrics Changes - Q4 2025 total revenue was $163 million, down 12% year-over-year, with clinical revenue growing by 32% and behavioral revenue declining by 17% [59] - Adjusted gross margin remained near record highs at 74.4% in Q4, slightly declining compared to Q3 due to seasonal staffing and a shift towards clinical services [60] - Adjusted EBITDA for Q4 was $18 million, reflecting an adjusted EBITDA margin of 11.1% [62] Business Line Data and Key Metrics Changes - End-of-period clinical subscribers reached 130,000 at the end of Q4, with expectations to end Q1 2026 with approximately 200,000 subscribers, indicating nearly 100% year-over-year growth [50][51] - End-of-period behavioral subscribers were 2.6 million at the end of Q4 2025, with an expected decline to approximately 2.45 million by the end of Q1 2026, representing a 26% year-over-year decrease [52][55] - Monthly subscription revenue per average subscriber (ARPU) increased by 8% year-over-year to $18.73 in Q4, with clinical ARPU being over four times higher than behavioral ARPU [57] Market Data and Key Metrics Changes - Approximately 10 million Americans are estimated to be on GLP-1 medications, with projections suggesting this could rise to between 25 and 50 million by 2030 [17] - The proportion of first-time Weight Watchers members in the U.S. increased to 35% across all programs in January, with 50% of new Med+ members being new to the Weight Watchers brand [39] Company Strategy and Development Direction - The company is transitioning from a behavioral subscription model to an integrated weight health ecosystem that includes medication access and clinical care [18] - Strategic focus areas include enhancing member experience, expanding medical offerings, and modernizing technology infrastructure [24][25] - The company aims to leverage its brand trust and scientific credibility while modernizing its approach to meet today's consumer needs [31] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to succeed post-reorganization, emphasizing the importance of integrating behavioral and clinical offerings [45][46] - The company acknowledges the challenges posed by the growing adoption of GLP-1 medications and aims to adapt its business model accordingly [40] - Management highlighted the importance of member engagement and the positive trends in member acquisition and retention [41][44] Other Important Information - The company eliminated over $1.1 billion of debt through financial reorganization, allowing for a refocus on investment and growth [48] - Marketing expenses in Q4 were 40% of revenue, reflecting increased spending to raise awareness of the Med+ offering [61] - The company expects revenue for fiscal year 2026 to be in the range of $620 million to $635 million, with adjusted EBITDA projected between $105 million and $115 million [70] Q&A Session Summary Question: Changes in demand for weight loss medications - Management noted a consistent trend of increasing consumer interest and adoption of GLP-1 medications, particularly with the introduction of lower-priced oral options [77][78] Question: Profile of new members and demographic changes - Management indicated that they are seeing younger members and lapsed members returning, with efforts to modernize the brand contributing to this trend [98][100] Question: Pricing strategy and promotional activities - Management discussed a shift in pricing strategy allowing long-term commitments to renew, which may impact ARPU but aims to stabilize membership [113][116] Question: B2B initiative and growth expectations - Management expressed enthusiasm about the B2B pipeline and partnerships, particularly with UnitedHealth Group, indicating a focus on expanding employer relationships [120][122]

Financial Data and Key Metrics Changes - The company eliminated over $1.1 billion of debt through a financial reorganization, allowing a refocus on investment and execution for the future [25] - Total revenue in Q4 was $163 million, down 12% year-over-year, with a 32% growth in clinical revenue and a 17% decline in behavioral revenue [31] - Adjusted gross margin remained near record highs at 74.4% in Q4, slightly declining compared to Q3 due to seasonal staffing and a shift towards clinical services [32] - Monthly subscription revenue per average subscriber (ARPU) increased 8% year-over-year to $18.73 in Q4, driven by the premium clinical business [30] Business Line Data and Key Metrics Changes - End-of-period clinical subscribers were 130,000 at the end of Q4, with expectations to reach approximately 200,000 by the end of Q1, indicating nearly 100% year-over-year growth [26] - End-of-period behavioral subscribers were 2.6 million at the end of Q4, with expectations to decline to approximately 2.45 million by the end of Q1, representing a 26% year-over-year decline [29] - The clinical business's ARPU remains over four times higher than the behavioral business, contributing to overall revenue dynamics [30] Market Data and Key Metrics Changes - Approximately 10 million Americans are estimated to be on GLP-1 medications, with projections suggesting this could rise to between 25 and 50 million by 2030 [7] - The company reported that 50% of new Med+ members were new to the Weight Watchers brand, indicating a successful brand repositioning [48] Company Strategy and Development Direction - The company is transitioning from a behavioral subscription model to an integrated weight health ecosystem that includes medication access and clinical care [8] - The focus is on building a connected ecosystem of solutions that facilitate member transitions across various offerings based on their specific goals [11] - The company aims to modernize its technology infrastructure and enhance member engagement through innovative digital tools and programs [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to succeed post-reorganization, emphasizing a commitment to helping members live healthier lives [24] - The company acknowledges the challenges posed by the growing adoption of GLP-1 medications, which may disrupt traditional behavioral alternatives [20] - Management highlighted the importance of integrating behavioral support with clinical offerings to enhance member outcomes and retention [22] Other Important Information - Marketing expenses in Q4 were 40% of revenue, reflecting increased efforts to raise awareness of the Med+ offering [32] - The company expects revenue for fiscal year 2026 to be in the range of $620 million to $635 million, with adjusted EBITDA projected between $105 million and $115 million [37] Q&A Session Summary Question: Demand for weight loss medications and the Wegovy pill - Management noted a consistent trend of increasing consumer interest and adoption of GLP-1 medications, particularly with the introduction of lower-priced options like the Wegovy pill [41] Question: Profile of new members and brand awareness - Management reported that 50% of new Med+ members are new to the brand, indicating successful brand repositioning and increased awareness of clinical offerings [48] Question: Changes in member sign-up lengths and demographics - Management observed a trend towards longer-term commitments in both clinical and behavioral businesses, with expectations for demographic expansion over time [59][60]

Financial Data and Key Metrics Changes - The company eliminated over $1.1 billion of debt through a financial reorganization, allowing a refocus on investment and execution for the future [25] - Total revenue in Q4 was $163 million, down 12% year-over-year, with a 32% growth in clinical revenue and a 17% decline in behavioral revenue [30] - Adjusted EBITDA for Q4 was $18 million, reflecting an adjusted EBITDA margin of 11.1% [32] - Monthly subscription revenue per average subscriber (ARPU) increased 8% year-over-year to $18.73 in Q4 [29] Business Line Data and Key Metrics Changes - End-of-period clinical subscribers were 130,000 at the end of Q4, with expectations to reach approximately 200,000 by the end of Q1, indicating roughly 100% year-over-year growth [26] - End-of-period behavioral subscribers were 2.6 million at the end of Q4 2025, with expectations to decline to approximately 2.45 million by the end of Q1, a decline of about 26% year-over-year [28] - The clinical business has a significantly higher ARPU, over four times that of the behavioral business [29] Market Data and Key Metrics Changes - Approximately 10 million Americans are estimated to be on GLP-1 medications, with projections of 25 to 50 million by 2030 [8] - The company reported a 30% increase in awareness of its Med+ offering following marketing efforts, indicating a successful repositioning of the brand [16] Company Strategy and Development Direction - The company is transitioning from a behavioral subscription model to an integrated weight health ecosystem that includes medication access and clinical care [9] - The focus is on creating a deeply engaging end-to-end member experience and innovating to capitalize on new technologies [11] - The strategy includes increasing levels of existing member migration across the portfolio and re-engaging lapsed behavioral members into Core+ and Med+ [28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to succeed and emphasized the importance of integrating clinical and behavioral support for long-term member outcomes [42] - The company is aware of the challenges posed by the growing adoption of GLP-1 medications and is adapting its behavioral business accordingly [20] - For fiscal year 2026, the company expects revenue to be in the range of $620 million to $635 million and adjusted EBITDA to be in the range of $105 million to $115 million [37] Other Important Information - The company has modernized its technology infrastructure and is focused on building a robust foundation for future growth and innovation [12] - Marketing expenses in Q4 were 40% of revenue, reflecting increased efforts to raise awareness of the Med+ offering [31] Q&A Session Summary Question: Changes in demand for weight loss medications - Management noted a consistent trend of increasing consumer interest and adoption of GLP-1 medications, particularly with the introduction of lower-priced oral options like the Wegovy pill [40][41] Question: Profile of new members and demographics - Management indicated that 50% of new Med+ members are new to the brand, with efforts to reposition the brand as a leader in medically-centric weight health [48][49] Question: Marketing strategy and demographics - The company is seeing younger members starting to come into the brand and is focused on expanding demographics over time [56][58] Question: Pricing strategy and promotional activity - Management discussed a shift in pricing strategy allowing members to renew long-term commitments, which may impact ARPU but is expected to stabilize over time [67][70] Question: B2B initiative and growth expectations - The company is optimistic about its B2B pipeline and is expanding partnerships, particularly with UnitedHealth Group, to enhance employer relationships [72][75]

Financial Data and Key Metrics Changes - In Q4 2025, total sales volume was 172,000 units, a 23.8% year-over-year decline [4][30] - Total revenue for the year reached RMB 4.31 billion, up 31% year-over-year [8][33] - Gross margin for the full year was 19.6%, an increase of 4.4 percentage points year-over-year [37] Business Line Data and Key Metrics Changes - In China, sales volume was 158,782 units, down 12% year-over-year, while international sales were close to 14,000 units, down 68% year-over-year [5][30] - For the full year, total sales volume reached 1.19 million units, a robust 29% year-over-year increase, with China sales surging 46% to surpass 1.11 million units [7][8] - The electric motorcycle segment represented more than 23% of total annual sales, driven by the success of the FX Windstorm model [10][11] Market Data and Key Metrics Changes - The overseas sales totaled 80,000 units for the full year, reflecting a 51% decline due to channel restructuring [8][25] - In Q4, international electric motorcycle sales surged to over 2,000 units, a 187% year-over-year increase [24] - The company activated over 100,000 scooters in the consumer market, indicating robust consumer demand [26] Company Strategy and Development Direction - The company is focusing on strategic transformation, including a shift to direct-to-retailer partnerships in key markets [4][6] - Plans for 2026 include scaling leadership in the electric motorcycle segment and launching tailored offerings for female riders and technology enthusiasts [13][27] - The company aims to prioritize long-term profitability over short-term volume in the micromobility segment [25][29] Management's Comments on Operating Environment and Future Outlook - Management anticipates a pronounced recovery in consumer demand as regulatory frameworks stabilize [27] - The company expects total sales volume for 2026 to reach between 1.67 million to 1.91 million units [29][43] - Management is confident in handling cost increases associated with new national standards through price adjustments and cost reduction initiatives [49][50] Other Important Information - The company has expanded its retail footprint to over 4,500 locations, with a focus on lower-tier cities [22] - The digital ecosystem has shown strong performance, with total online sales reaching approximately 500,000 units [22][23] - The company plans to unveil an AI-enabled smart scooter at an upcoming product launch event [18] Q&A Session Summary Question: Current inventory situation for kick scooters in overseas markets and outlook for 2026 - The company reported around CNY 650 million in total inventory, with over 50% being aged kick scooters. The focus for 2026 will be on improving inventory turnover rather than introducing new models [47][48] Question: Potential cost increase due to new national standards for e-scooters - Management acknowledged that there will be cost increases but plans to adjust retail prices and implement cost reduction initiatives to manage these increases effectively [49][50]

Financial Data and Key Metrics Changes - CytomX Therapeutics reported positive phase I dose expansion data for Varseta-M in late-line colorectal cancer, with a confirmed overall response rate of 32% at 10 mg/kg and 20% at 8.6 mg/kg [14][19] - The preliminary progression-free survival (PFS) improved from 5.8 months in May 2025 to 6.8-7.1 months [14][19] - The company aims to rapidly advance Varseta into its first registrational study, targeting a significant market opportunity in late-line colorectal cancer with over 45,000 addressable patients by 2040 [31][32] Business Line Data and Key Metrics Changes - Varseta-M is designed to target EpCAM, which is highly expressed in colorectal cancer, and aims to address the unmet need in this market [10][31] - The drug's development strategy includes aggressive advancement into earlier lines of therapy, potentially replacing irinotecan [31][32] Market Data and Key Metrics Changes - Colorectal cancer is projected to grow from 1.9 million diagnoses per year to over 3 million by 2040, with a significant market opportunity for Varseta-M [7][8] - The current standard of care in late-line metastatic colorectal cancer has low objective response rates, highlighting the need for more effective treatments [9][31] Company Strategy and Development Direction - CytomX plans to expand Varseta-M into early-line colorectal cancer and other EpCAM-positive tumors, leveraging the success in colorectal cancer as a foundation for broader applications [31][32] - The company is focused on optimizing dosing strategies and prophylactic measures to enhance the safety profile of Varseta-M [23][29] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the drug's performance and its potential to transform treatment paradigms in colorectal cancer [30][31] - The company is committed to rapid execution of registrational studies and anticipates sharing additional data in the near future [32][33] Other Important Information - The safety profile of Varseta-M has shown no evidence of classic EpCAM toxicities, and the incidence of grade 3 diarrhea has been reduced through updated prophylactic strategies [14][25] - The drug's pharmacokinetics support dose optimization based on adjusted ideal body weight to improve consistency and efficacy [27][28] Q&A Session Summary Question: What is the anticipated size of the pivotal trial? - Management indicated that the pivotal study size is still under consideration, but they are encouraged by the activity levels observed in late-line colorectal cancer [38][39] Question: What are the potential indications beyond colorectal cancer? - Management highlighted the potential for Varseta-M in other solid tumors, including gastric and pancreatic cancers, and expressed excitement about the broader applications of EpCAM targeting [40][41] Question: How will the prophylactic protocol be implemented in real-world settings? - Management noted that the dual prophylactic strategy of loperamide and budesonide is expected to be well-adhered to in clinical practice, especially given the convenience of oral administration [46][70] Question: Will progression-free survival be the primary endpoint in the pivotal trial? - Management confirmed that overall survival is expected to be the primary endpoint, although they are open to exploring other options as the data matures [48][49] Question: How does Varseta-M compare to other ADCs in development? - Management emphasized that Varseta-M is a first-in-class anti-EpCAM ADC and believes it may be the best-in-class option for colorectal cancer based on current data [53][54]